The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Rheumatology Fellow Shares Her Journey to Capitol Hill via the ACR’s Advocacy 101 Program

A Rheumatology Fellow Shares Her Journey to Capitol Hill via the ACR’s Advocacy 101 Program

November 18, 2018 • By Courtney B. Crayne, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Brandon Bourdages / shutterstock.com

Brandon Bourdages / shutterstock.com

In summer 2017, I was a few months post-partum when I received an email announcing applications for the ACR’s Advocacy 101 program. It would take only a few days, but I asked my division director if it would be worth the time commitment. He questioned the career benefits of advocacy, but encouraged me to apply my outspoken personality toward improving patient care.

You Might Also Like
  • ACR’s 2018 Advocates for Arthritis & Advocacy 101 Program
  • Rheumatology Advocates to Visit Capitol Hill
  • Rheumatology Professionals and Patient Advocates Take Their Stories to Capitol Hill
Explore This Issue
November 2018

More than one year later, I continue to advocate for arthritis and remain enthusiastic about improving access to quality medical therapy. Although advocacy does not provide financial reimbursement, per se, the benefits to our patients, our subspecialty and, ultimately, our careers are indisputable.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Program Explained

The Advocacy 101 (A101) program occurs in conjunction with Advocates for Arthritis (A4A) during September (i.e., Rheumatic Disease Awareness Month) and serves as a boot camp for fellows in training and fellowship program directors to educate and engage participants in healthcare policy and patient advocacy. The program begins with a casual welcome reception, allowing fellows a chance to network with the planning committee, as well as other fellows from pediatric and adult training programs. The first day is packed full of lectures, designed to educate advocacy newbies on the major components of healthcare policy and the challenges we face as clinicians. The day concludes with a large networking dinner, including A101 participants, members of the Government Affairs Committee (GAC), RheumPAC and the ACR Executive Committee.

The second day continues with educational lectures as part of the larger A4A program, which includes former A101 graduates, practicing rheumatologists, members of the interprofessional team (e.g., physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists) and patient advocates. The latter half of the session is interactive, allowing advocates an opportunity to meet their team members (often grouped by state), with whom they will spend the next—and final—day advocating on Capitol Hill.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The GAC preselects three major issues to present to lawmakers, and ACR staff members assist in scheduling meetings with members of Congress. The A101 and A4A programs prepare advocates for their big day on the Hill by reviewing expectations and prepping them on the three issues at hand. Although it seems overwhelming, committee and staff members work diligently to ensure all advocates are well prepared to discuss the current issues with legislators and fight for better patient care.

This Year

This year, we focused on step therapy legislation, dedicating medical research funding to arthritis in the Department of Defense’s (DoD’s) Congressionally Directed Medical Research Program and improved access to osteoporosis testing in Medicare. Specifically, we advocated for co-sponsorship of H.R. 2077 (https://tinyurl.com/y8zkm39b), a proposed law that seeks exceptions to step therapy and provides a reasonable and clear timeframe for insurance companies to assess the patient prior to denying medically necessary therapy, and we asked our senators to introduce companion legislation. This initiative piggybacks on our recent success within the U.S. Senate following a 98 to 2 vote on the pharmacy benefit manager gag clause bill, which prohibits Medicare insurers from banning pharmacies to inform patients that their prescription drugs would be cheaper if they were to pay out of pocket rather than through their insurance. This win is a huge leap toward drug-pricing transparency. In combination with step therapy legislation, we aim to progress toward individualized therapy for our patients (i.e., treat the patient and not the insurance policy).

Pages: 1 2 3 | Single Page

Filed Under: Legislation & Advocacy Tagged With: Legislation & AdvocacyIssue: November 2018

You Might Also Like:
  • ACR’s 2018 Advocates for Arthritis & Advocacy 101 Program
  • Rheumatology Advocates to Visit Capitol Hill
  • Rheumatology Professionals and Patient Advocates Take Their Stories to Capitol Hill
  • ACR Hosts Arthritis 101 Briefing on Capitol Hill

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)